Status:
TERMINATED
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Metastatic Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This study of hormone positive (estrogen receptor \[ER\]), metastatic invasive ductal breast cancer looks at functional scanning using positron emission tomography (PET) and patient response to hormon...
Detailed Description
Primary objective: To determine the utility of pre-treatment (16 alpha\[18-F\]-fluoroestradiol) FES-PET and routine (\[18-F\]-fluorodeoxy-D-glucose) FDG-PET in the prediction of response to hormone th...
Eligibility Criteria
Inclusion
- Metastatic invasive ductal ER positive breast cancer
- All adjuvant treatment must have been completed at least 3 months prior to study entry.
Exclusion
- Patients who do not have the primary tumor subtype of invasive ductal adenocarcinoma
- Patients with only loco-regional recurrence
Key Trial Info
Start Date :
August 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT00358098
Start Date
August 1 2006
End Date
June 1 2013
Last Update
June 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2